



Press release from Emotra AB (publ)
Göteborg, November 16, 2018

Emotra signs a letter of intent with a psychiatric hospital in England

Emotra hereby announces that the company has signed a letter of intent with a large, London-based psychiatric hospital. This deal grants the hospital the right to use EDOR® during a limited trial period. The agreement includes 30 tests free of charge, after which Emotra will be compensated for each test analysis.

Their evaluation will begin as soon as the involved physicians and test leaders have received training on the method, which according to our preliminary plans will be at the end of November. The goal of their evaluation is to investigate how the method fits in with the hospital's regular procedures. They want to assess Emotra's method on a limited scale to determine how they, in practice, would organise such testing, manage the analysis results, as well as how they could best apply this technology in their patient care workflows. Their goal is to gain some initial experience and then evaluate how it affects their organisation, communication and patient care before they move on to the next step. It is important to point out that this evaluation concerns a controlled implementation in clinical practice; it does not concern the performance of a clinical study.

Comments from Daniel Poté, our CEO

"The fact that we, in such a short period of time, have come so far in the process with one of London's leading, privately-owned psychiatric hospitals is a victory in itself, and will support us in our continued marketing efforts. We have learned many valuable lessons from our marketing efforts this year. This deal confirms the wisdom of our decision to concentrate our marketing efforts on London and other major metropolitan areas in Europe. These cities are home to clinics and hospitals that are able to make a decision to implement EDOR in their clinical practice. Provided that the experience for the first hospitals that choose to regularly test patients with EDOR is positive, we see an excellent opportunity to leverage that experience in our next step of working the broader hospital market."

This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation and the Securities Market Act. This information was submitted for publication on November 16, 2018 under the above contact's supervision.

For further information, please contact: Daniel Poté, CEO, telephone: +46 732 34 41 93, E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression